Stock Detail
Videos
Reviva Pharmaceuticals (RVPH) Company Webcast
Reviva (Nasdaq: RVPH) is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current...
Reviva Pharmaceuticals (RVPH) Fireside Chat
During this fireside chat webcast, we welcome Reviva Pharmaceuticals, ticker symbol RVPH on the NASDAQ. Joining us today from the company is Lax Bhat, Reviva's Chief Executive Officer. Also joining us is Jim Molloy, Senior Research Analyst with Alliance Global...
Reviva Pharmaceuticals (RVPH) Fireside Chat
During this fireside chat, we welcome Reviva Pharmaceuticals, ticker, RVPH on the NASDAQ, and their CEO, Dr. Lax Bhat. Reviva is a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system...
News
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
CUPERTINO, Calif., Dec. 16, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Proposed Public Offering
CUPERTINO, Calif., Dec. 16, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
- Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year - - Generally well-tolerated with low rates of adverse events and discontinuation - - Full data set from open-label extension (OLE) of RECOVER...